Cyclin D3 (CCND3) (full length) antibody

Antigen: Cyclin D3 (CCND3)

Synonyms: CYCE2, C78795, AA682053, AL024085, AW146355, 9230106B05Rik, MGC93643, MGC108760, zgc:103502, CCND3, MGC128700, LOC780426

Binding Site: full length

Clonality: Monoclonal (G107-565)

Host: Mouse

Reactivity: Human

Conjugate: Un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunoprecipitation (IP)

Catalog no.: ABIN967432

Additional Information

Alternative name: Cyclin D3

Immunogen: Recombinant full-length human cyclin D3

Format: Liquid

Isotype: IgG1

Clone: G107-565

Description: Cyclins and cyclin-dependent kinases (cdks) are evolutionarily conserved proteins that are essential for cell-cycle control in eukaryotes. Cyclins (regulatory subunits) bind to cdks (catalytic subunits) to form complexes that regulate the progression of the cell cycle. The main cyclin-cdks complexes formed in vertebrate cells are cyclin D-cdk4 (G0/G1), cyclin E-cdk2 (G1/S), cyclin A-cdk2 (S) and cyclin B1-cdk1 (G2/M). These complexes are regulated by activating and inhibitory phosphorylation events, as well as by interactions with small proteins that bind to cyclins, cdks, or cyclin-cdk complexes, e.g., p21 and p27Kip1. Specific substrates for cdk-cyclin complexes include nuclear lamins, histones, oncogenes (c-src, c-abl, SV40 large TAg), tumor suppressor genes (e.g., retinoblastoma protein [Rb] and p53), nucleolin, RNA polymerase II and others. It is thought that D-type cyclins are involved in regulating the passage of mammalian cells through G1. The reduced molecular weights of D-type cyclins are as follows: cyclin D1 (36 kDa), cyclin D2 (35 kDa) and cyclin D3 [31 and 34 kDa (doublet)]. G107-565 recognizes human cyclin D3. It does not cross-react with human cyclins D1 or D2.

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Molecular Weight: 31/34 kDa doublet

Application Details

Application Notes: D-type cyclins are differentially expressed in distinct cell types. Cell types which have been documented to express high levels of a given D-type cyclin are suggested as positive controls. WI-38 human diploid fibroblasts (ATCC CCL-75) and U-118 (ATCC HTB-15) are suggested as positive controls for detecting cyclin D1 and D3. Primary human peripheral blood T lymphocytes stimulated with phytohemagglutinin (PHA) are also good positive controls for detecting cyclin D3. The conjugated format of the clone is recommended for use in staining and flow cytometry.

Concentration: 0.5 mg/ml

Purity: Purified

Purification: Purified from tissue culture supernatant or ascites by affinity chromatography.

Buffer: Aqueous buffered solution.

Preservative: 0.09% Sodium azide.

Storage: Store undiluted at 4°C.

Research Area: Cancer, Cell Cycle

Restrictions: For Research Use only

Images

Western blot analysis of cyclin D3. Lysate from K-562 human leukemia cells was probed with anti-cyclin D3 (clone G107-565, ABIN967432) at concentrations of 1.0, (lane 1), 0.1 (lane 2), and 0.01 µg/ml (lane 3). Cyclin D3 is identified as a band of ~34 kDa.

anti-Cyclin D3 (CCND3) (full length) antibody (Image 2)

Publications

Gong, Traganos, Darzynkiewicz: "Threshold expression of cyclin E but not D type cyclins characterizes normal and tumour cells entering S phase." in: Cell proliferation, Vol. 28, Issue 6, pp. 337-46, 1995 (PubMed).

Gong, Bhatia, Traganos et al.: "Expression of cyclins A, D2 and D3 in individual normal mitogen stimulated lymphocytes and in MOLT-4 leukemic cells analyzed by multiparameter flow cytometry." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 9, Issue 5, pp. 893-9, 1995 (PubMed).

Shapiro, Edwards, Kobzik et al.: "Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines." in: Cancer research, Vol. 55, Issue 3, pp. 505-9, 1995 (PubMed).

Rao, Kohtz: "Positive and negative regulation of D-type cyclin expression in skeletal myoblasts by basic fibroblast growth factor and transforming growth factor beta. A role for cyclin D1 in control of myoblast differentiation." in: The Journal of biological chemistry, Vol. 270, Issue 8, pp. 4093-100, 1995 (PubMed).

Meyerson, Harlow: "Identification of G1 kinase activity for cdk6, a novel cyclin D partner." in: Molecular and cellular biology, Vol. 14, Issue 3, pp. 2077-86, 1994 (PubMed).

Sherr: "Mammalian G1 cyclins." in: Cell, Vol. 73, Issue 6, pp. 1059-65, 1993 (PubMed).

Darzynkiewicz, Gong, Juan et al.: "Cytometry of cyclin proteins." in: Cytometry, Vol. 25, Issue 1, pp. 1-13, 1997 (PubMed).